GeneDx Holdings Corp. (WGS) Stock

GeneDx Holdings Corp., operating under the name GeneDx, functions as a leading health information company dedicated to advancing disease diagnosis, treatment, and prevention through innovative data solutions. Our flagship platform, Centrellis, harnesses AI-driven health intelligence to empower biopharma companies with comprehensive insights. This includes accelerating the entire drug discovery, development, and commercialization lifecycle, alongside offering analytics for actionable insights and robust support for pre-clinical and clinical trials. GeneDx also specializes in advanced sequencing services, enhancing precision and efficacy across various medical applications.

At the core of our offerings is Sema4 Signal, a pioneering tool that revolutionizes precision oncology care from prevention through treatment to remission. GeneDx excels in genetic testing services, encompassing carrier screening, noninvasive prenatal testing, newborn screening, and hereditary cancer testing. Our commitment extends to providing essential COVID-19 testing solutions, reinforcing our dedication to addressing contemporary healthcare challenges with cutting-edge technology and expertise.

Founded in 2020 and headquartered in Stamford, Connecticut, GeneDx Holdings Corp. stands at the forefront of leveraging data-driven insights to redefine healthcare outcomes. With a steadfast focus on innovation and precision medicine, we continue to lead the industry in transforming patient care and enhancing therapeutic development through advanced genomic and health intelligence solutions.